PTPN11 and cancer: The excitement about dual CDK4/6-SHP2 inhibition has even led to clinical testing of ribociclib (CDK4/6 inhibitor) plus TNO155 (SHP2 inhibitor) in patients with NF1-deficient cancers (NCT04000529).